Internal medicine at the crossroads of long COVID diagnosis and management

The lack of specificity in its definition is a major obstacle to both explanatory and therapeutic research in long COVID. It brings together, on the one hand, patients with severe COVID-19 who suffer the classic complications of prolonged hospitalization and decompensation of comorbidities and, on the other hand, patients with non-severe acute COVID-19 who report multiple symptoms that cannot be fully explained by a biomechanical model. Indeed, despite numerous studies, it remains unclear how persistent viral infection, immunological or coagulation disturbances may contribute mechanistically to long COVID. Nevertheless, internal medicine should be in good place to manage these patients. Indeed, the diversity of symptoms may evoke a broad spectrum of differential diagnoses that are familiar to internists. Their experience in the exploration of unexplained symptoms is also valuable. It can reduce the need for multiple consultations with specialists and unnecessary laboratory or imaging tests. However, long COVID diagnosis cannot be limited to the exclusion of all other conditions one by one. An open and non-dualistic approach is required to identify other mechanisms that may explain the symptoms. Based on their clinical experience, most French internists who responded to an opinion survey consider that long COVID corresponds most closely to a functional somatic disorder (FSD) and seek the help of specialists in mental health care to assist in the management of the patients in a multi-disciplinary approach. However, as with other FSDs, patients with long COVID are usually reluctant to be managed by mental health care specialists, given the very physical nature of their presentation. Unfortunately, most physicians are in turn reluctant to take care of them, due to poor knowledge about FSD, leading to management failure. Alternatively, a comprehensive multidisciplinary care orchestrated by an experienced internist is generally well-accepted. It includes providing rational cognitive explanations for the symptoms and support for behavioral changes tailored to the patient. While waiting for hypothetical randomized controlled trials assessing drugs with positive results, such a holistic approach has been successfully applied in many individuals with severe long COVID. However, its generalization would require a much broader training for FSD of all health care providers.

Introduction

Long COVID is considered a public health problem, since its incidence was estimated as high as 10% among patients infected by SARS-CoV-2 (1). More recent data suggest a gradual reduction in the risk over time. The cumulative incidence of long Covid during the first year after infection was estimated to be 10 events per 100 persons in the pre delta period, 7.8 events per 100 persons in the omicron period, and about 3.5 events per 100 persons during the omicron era in vaccinated individuals (2). Noteworthy, this incidence decrease was actually independent of SARS-CoV-2 genetic variant since it was also observed between the first and second epidemic waves that involved the same variant in 2020 (3). However, prevalence estimations may vary greatly depending on the definition used (4). Indeed, although the main symptoms of long COVID reported by patients and the literature are fatigue, respiratory disturbances and cognitive issues (such as “brain fog”), a multitude of unspecific symptoms has been reported (5). According to the WHO definition established by Delphi method, there is neither a maximum timeframe for its onset after COVID infection—although it is stated that symptoms “usually occur 3 months from the onset of COVID-19” —nor a necessity for proof of SARS-CoV-2 infection to retain the diagnosis (6). Therefore, any unexplained symptom that occurred after March 2020 and lasted more than 2 months potentially meets the definition of long COVID.

A critical approach to literature

A wealth of medical literature has developed since the summer of 2020 regarding the potential causes of long COVID, which is particularly difficult to synthesize due to significant heterogeneity. This might partly be due to publication bias and frequent methodological flaws.

First, as mentioned above, the lack of specificity of the long COVID definition allows very dissimilar populations to be included in studies. The early studies primarily included patients who had been hospitalized for severe COVID (7). These patients often had objective pulmonary sequelae and non-specific physical sequelae due to prolonged hospitalization (malnutrition, muscle atrophy, post-traumatic stress…). Then, studies tended to mix this population and patients who were not hospitalized for COVID-19, some of whom did not even have confirmed SARS-CoV-2 infection due to the lack of availability of testing in the community during the early months of the epidemic (5). It is this second population that poses a real problem due to the absence of an obvious cause for symptoms that can nevertheless be severe and very disabling. Unlike the post-hospitalization population, the majority are women, with an average age between 30 and 50 years (compared to over 60 years for hospitalized patients) and few comorbidities. Unfortunately, most translational studies on long COVID do not describe how patients were recruited, nor their clinical characteristics, and do not adjust their statistical analyses for the presence of comorbidities, even though these could explain part of the results (8–10). The early immunological studies also did not include an appropriate control group: they compared healthy subjects who had never been infected with COVID to patients with long COVID and found higher level of inflammation in patients (11), while it is now well established that sub-clinical inflammation markers decrease after infection but can persist in the human body for several months, independently of the persistence of symptoms (10, 12, 13). Therefore, the appropriate control group is patients who were infected by Sars-Cov-2, but did not have persistent symptoms with the same follow-up time since infection than patients with long COVID. Furthermore, immunological studies involve numerous cytokine assays, cellular phenotyping, transcriptome studies, etc., using modern multiplex methods, but very few consider the alpha risk inflation (false positive results) due to the multiplication of statistical tests. Additionally, most of them only highlight positive results and fail to discuss negative findings that contradict other publications (8–12). Finally, even in the case of statistically significant differences, the distributions of biological marker concentrations largely overlap between cases and controls, preventing their use as prognostic or diagnostic markers. Thus, although many immunological markers have been shown to be marginally but differentially distributed between cases and controls, none have been consistently replicated to date (10–12, 14). Consequently, no consensus can be reached regarding the potential specific immunological mechanisms at play in the genesis of long COVID (15).

Similarly, early studies exploring viral persistence were conducted without controls or with inappropriate controls (patients who had never been infected) or at an early stage (less than 3 months symptoms duration). Some of them suggested that viral persistence could explain long COVID based on the presence of SARS-CoV-2 RNA in olfactive bulbs, digestive biopsies or feces (16). However, subsequent studies including patients with or without persistent symptoms after COVID-19 did not find evidence of longer viral persistence in those with persistent symptoms (12, 17). One recent study investigated the persistence of viral RNA in various tissue samples of patients who had mild COVID-19. A significant association has been identified between the detection of viral RNA in at least one tissue and the presence of long COVID symptoms. This association strongly decreased between 1 and 2 months after infection and was no more significant 4 months after infection (18).

Regarding the specific aspect of central nervous system (CNS) involvement, it is important to note that persistence of SARS-CoV-2 in the CNS has never been directly described in long COVID. Studies suggesting the presence of SARS-Cov-2 in the brain have been conducted using autopsies of patients who died of severe acute COVID-19. They found CNS symptoms such as hemorrhagic infarction, microglial activation and neuronal phagocytosis, but detectable levels of virus in the brain were very low and not associated with histopathological changes (19). Furthermore, while in vitro studies have suggested several theoretical pathways by which this virus may enter the CNS, clinical studies suggest that direct invasion of the CNS by SARS-CoV-2 is rare and extremely limited. Nevertheless, it is possible that the SARS-CoV-2 spike (S) protein has direct inflammatory and procoagulant effects. The addition of cytokine release syndrome (CRS) with loss of blood–brain barrier integrity may contribute to the expression of pro-inflammatory mediators by neural cells that may affect brain function (20). However, as the presence of Sars-Cov-2 RNA in other tissues, markers of CNS damage do not correlate with long-term clinical symptoms. For example, a study comparing the CNS effects of the virus during the acute phase of COVID-19 and six months later found that plasma concentrations of neurofilament light chain (sNfl) and glial fibrillary acidic protein (GFAp) normalized, while a large number of patients continued to have neurological and cognitive symptoms (21). A notable exception may be noted for persistent anosmia/ageusia, which correlates with evidence of viral material and inflammation in olfactive bulbs/tongue biopsies (22, 23). It should also be noted that prolonged viral persistence has been well (and easily) documented in patients who are severely immunocompromised (notably organ transplant recipients), who also have a very different clinical presentation and evident paraclinical anomalies (18, 24). In contrast to studies using ultra-sensitive biological techniques not commonly used in current practice (mostly dosage of plasma cytokines by multiplex essay or leukocyte immunophenotyping by flow cytometry), studies published by clinicians consistently failed to demonstrate biological difference between patients infected by COVID-19, with and without persistent symptoms (17, 25–30).

Last, 4 years after the clinical characterization of long COVID, no efficient pharmacological treatment has been reported (31, 32). In particular, unlike in acute COVID-19, neither antiviral drugs, anti-SARS-CoV-2 monoclonal antibodies, nor immunosuppressive drugs such as steroids or interleukine-6 inhibitor have proved efficient in long COVID (33, 34).

By contrast, certain non-biological risk factors have been regularly identified in patients with long COVID and mild initial COVID-19, such as female sex and the number of initial symptoms (29, 35), the history of anxiety or depressive disorders (28, 36–39), or negative feelings regarding COVID-19, such as the COVID-related anxiety (40), the burden associated with symptoms of acute COVID (41), and the fear that acute symptoms will persist (42). It is unfortunate that this non-somatic dimension is completely ignored, even in the most recent high-quality reviews of the causes of long COVID (1, 43).

Arguments for a functional disorder

For patients who search for information on the internet, or for doctors who are not expert clinicians, the combination of long COVID symptoms may evoke several rare pathologies: systemic immunological diseases (lupus, vasculitis, connective tissue diseases, autoinflammatory diseases, etc.), hematological conditions (mast cell activation syndrome…), infectious or genetic diseases (cryopyrinopathies, interferonopathies…). However, unlike patients suffering from these biologically explained diseases, patients with long COVID do not present objective clinical signs that would allow their diagnosis. Most symptoms are either subjective or compatible with a dysfunction of the autonomic nervous system (hyperventilation, postural orthostatic tachycardia syndrome…), but without criteria of severe dysautonomia (38, 44). Furthermore, in patients without history of severe acute COVID-19, there is no abnormal biological or imaging findings or they cannot entirely explain the symptoms (13, 17, 26–30). As mentioned above, one exception is anosmia and dysgeusia, that are associated with pathological findings at MRI and nose or tongue biopsies (23, 45) and probably arise from direct neurological viral toxicity. For other symptoms than anosmia and dysgeusia, the only abnormal results that are frequently observed are hypometabolisms of right medial temporal lobes (hippocampus and amygdala), right thalamus brainstem and cerebellum at brain PET scans (46), whose interpretation is controversial. Indeed, there is no established correlation with the type and intensity of symptoms (47) and the cause of the observed anomalies could be organic or functional (48).

The clinical picture of long COVID, on the other hand, has strong semiological similarities with other biomedically unexplained conditions that have different presumed causes (like chronic Lyme disease, hypersensitivity to electromagnetic waves or chemicals, etc.) or are defined by a main symptom (fatigue for myalgic encephalomyelitis/chronic fatigue syndrome, pain for fibromyalgia, etc.). It is commonly, though not unanimously accepted, that these entities are part of the broader group of “functional somatic disorders” (FSD) (49). FSD are usually defined as patterns of persistent bodily complaints for which adequate examination does not reveal sufficiently explanatory structural abnormality or other specified pathology, with severe impact on functioning and quality of life (49–51). FSD vary in names based on the predominant symptoms and the medical specialty involved (e.g., irritable bowel syndrome in gastroenterology, hyperventilation syndrome in pneumology, fibromyalgia in rheumatology, chronic fatigue syndrome in internal medicine….). They represent the medical side of the psychiatric nosologic category “somatic symptom disorder” in DSM V (50). Importantly, FSD is often triggered by a somatic illness (in particular an infectious disease) but also involves brain conditioning along with socio-psychological predisposing factors (perfectionism, alexithymia, childhood traumatic experience…). Most importantly the long term persistence of symptoms is favored by cognitive (involuntary attentional focusing on symptoms, catastrophism, illness-related anxiety, feeling of rejection…) and behavioral factors, including avoidance of physical effort that leads to physical deconditioning as well as avoidance of uncertainty that leads to never-ending request for medical tests and consultations (51, 52). These conditions can be associated to varying degrees in the same person, suggesting shared transdiagnostic mechanisms (49, 51), Thus, the term “bodily distress syndrome” (International Classification of Diseases 11), has been suggested as a more neutral term to cover them all (53). Strikingly, bodily distress syndrome shares all its symptoms with those that are most common in long COVID (see Table 1).

Table 1

Table 1. Diagnostic criteria for bodily distress symptoms.

A significant number of symptoms observed in patients with long COVID are also similar to those found in people suffering from post-traumatic stress disorder (PTSD). In particular, experiencing neurocognitive symptoms, such as difficulties with memory and thinking, after mild COVID-19 infection was strongly associated with the presence of persistent PTSD-like symptoms (54). The occurrence of PTSD is common in the context of infectious epidemics (55) Noteworthy, in contrast to patients with FSD, patients with PTSD experience flashbacks—reliving the traumatic COVID episode, or have recurring memories or dreams related to this acute COVID episode. Therefore, this condition is essentially observed in patients who have dealt with severe COVID-19 (56).

In our clinical center dedicated to long COVID in Paris, after standardized multidisciplinary evaluation, 76% of patients who had mild acute COVID-19 and exhibited prolonged symptoms (median duration 429 days) meet the criteria for FSD (57). This observation has been shared by other clinicians worldwide (58–60). In our experience, 21% patients were also diagnosed with (i) anxiety (including panic disorders, whose manifestations are primarily physical) or (ii) depressive disorders that account for their symptoms, (iii) with or without associated FSD. This is consistent with a recent meta-analysis reporting a global prevalence of depression and anxiety in 23% of patients with long COVID (61). In our cohort, only a minority of patients (10%) did not fit into one or more of these three diagnoses, most of them having another condition explaining the symptoms, unlinked to COVID-19 (57).

A final argument in favor of the FSD hypothesis is that to date, only cognitive behavioral therapy and gradual physical activity have proven effective in treating long COVID (34). It is noteworthy that, whereas nirmarelvir/ritonavir was reported as inefficient as a curative for long COVID (33), it has been successfully tested as a preventive treatment (62). This finding is not surprising even in the hypothesis of FSD, as nirmarelvir/ritonavir decreases the intensity and the number of symptoms of the acute episode of SARS-CoV-2, which are risk factors for long COVID.

Current management of patients with long COVID symptoms

In Belgium, the management of long-COVID is primarily predicated on a personalized care pathway, which is funded by the Ministry of Health. As also recommended in French national guidelines (63), this care is coordinated by the general practitioner, who refers patients to various health professionals, including physiotherapists, ergotherapists, neuropsychologists, and dieticians.

Unfortunately, many physicians are reluctant to handle these patients, who often require considerable time and attention, leading to diagnostic and therapeutic failures. Many tend to rid themselves of the problem either by dismissing the legitimacy of the complaint (“you do not have anything!” or “it will pass on its own!”), or, on the contrary, by conducting numerous tests and requesting many specialized opinions to reduce their own uncertainty, out of fear of missing a serious illness (64). This second attitude is understandable to the novelty of COVID-19 infection, its pleiomorphism and sometimes alarming scientific literature. However, this diagnostic quest quickly becomes detrimental for the patients. Both attitudes aggravate the situation, with the first intensifying feelings of rejection and the second exacerbating catastrophizing, both worsening the attentional focus on symptoms, which perpetuates or even exacerbates symptoms. In the doctors’ defense, an exhaustive search—though impossible—is often advocated by the patients themselves.

Indeed, patients with FSD spontaneously consult doctors because of the physical nature of their symptoms and are generally reluctant to be referred to mental health specialists. Even when patients do accept a psychiatric assessment, the psychiatrist most often focuses on the identification and treatment of classical psychiatric disorders (anxiety, depression, etc.), which affect only a minority of patients. Few psychiatrists are trained to actively seek out FSD and fear misattributing physical symptoms to a psychological cause. A “return to sender” is therefore common, further reinforcing the patient’s belief in an exclusively somatic cause (51, 64). This path marked by non-recognition and medical nomadism is that of patients with long COVID and is an integral part of their problem. In fact, in most countries, the notion of FSD is very poorly understood and is often equated with a psychiatric illness, or attributed exclusively to the patient, or at worst, seen as malingering. This leads to significant hetero and self-stigmatization, as well as a feeling of non-recognition or even humiliation, which perpetuates the need to prove the reality of the symptoms and to search for an external, or at least physical, cause.

There is indeed a major training deficit for FSD in somatic physicians, psychiatrists, psychologists, physiotherapists, and the general population. One of the problems is the poor reputation of psychiatric illnesses and the belief in a body/mind duality, which often leads to the rejection of any “psychologizing” explanation. Recently, a German team proposed a very integrative vision of persistent physical symptoms (PPS)—that is, symptoms lasting several months, regardless of their cause (52)—which seems to particularly apply to long COVID. These symptoms affect up to 9% of the general population. The more they persist, the more their link to a pathophysiological cause weakens. Examples include persistent digestive symptoms after the remission of chronic intestinal disease, hyperventilation syndrome distinct from co-existing asthma, or chronic fatigue syndrome following a viral infection. The factors of chronicity are biological (e.g., low-grade inflammation, alterations in microbiome…), cognitive-perceptual and emotional (e.g., symptom focus, catastrophism, alexithymia, health-centered anxiety), behavioral (e.g., physical deconditioning due to inactivity and avoidance behaviors), and related to interaction with the health system (e.g., drug side effects and conflicting relationships with health care professionals). There is a continuum between physical and psychological causes, but even diseases with a well-accepted pathophysiological explanation, such as systemic lupus erythematous, multiple sclerosis or spondyloarthropathy, are strongly modulated by cognitive-behavioral factors. When there is a discrepancy between a high symptom burden and normal clinical and paraclinical exams, these PPS meet the criteria for FSD.

We believe that this vision is capable of reconciling patients and doctors, based on a shared and accepted diagnosis. It allows them to focus on the essential, which is the personalized search for effective therapeutic solutions. In our experience and that of many colleagues, acceptance of the diagnosis is very good if it is explained in a positive and scientific way, with empathy and without judgment (65). This includes providing rational cognitive explanations for the symptoms and support for behavioral changes, such as stopping medical explorations and resuming exercise very gradually.

What place for the general internist in the management of patients with long-COVID?

Because of the multiplicity of possible causes, internists have several assets that should in theory allow them to take good care of patients with long COVID who do not improve after a first line treatment by their general practitioner. First, they have large semiology skills and good knowledge of the potential differential diagnoses (including immunological, metabolic and multi-system infectious diseases) that should allow them to avoid unnecessary and deleterious examinations if the clinical presentation is incompatible.

In France, the post graduate teaching of internal medicine is coupled with that of clinical immunology for 5 years. Unfortunately, French internists are also often guilty of excessive diagnostic work-up, which is sometimes poorly related to symptoms. However, they are used to coordinating care with other specialists, thus avoiding or at least reducing medical nomadism. They also usually have a genuine willingness to achieve holistic care. Finally, they have a long-standing experience with patients with unexplained symptoms, including many patients with FSD who consult them in the hope for a new diagnostic.

However, internists’ views on long COVID are far from unanimous. Recently, we performed an online survey of French senior internists, that showed that beliefs are disparate. Among 240 responders (females 42%), representing all French regions, age groups and type of medical practice (Supplementary Figures 1, 2), 214 (89%) considered that long COVID may be an FSD. They also think other causes may be associated, such as physical deconditioning (77%), post-traumatic stress (41%), anxio-depressive disorder (43%), dysimmune disease (23%), SARS-CoV-2 persistence (8%) or other miscellaneous hypotheses (Figure 1). When they were asked to choose a primary cause, 63% chose FSD, 19% physical deconditioning, and only 9% biological cause (Figure 2).

Figure 1

Figure 1. Possible causes for long COVID considered by senior internists in France. The figure presents the findings of a survey conducted among senior internists who are members of the French Society of Internal Medicine regarding the causes of long-term symptoms associated with long COVID. By the close of March 2025, a total of 240 responses had been documented through a Google Form platform, accessible via an access link. Participants were invited to identify one or more possible causes of long COVID, which are shown on the x-axis. The figure illustrates the proportion of respondents (both male and female) who consider each of the eight propositions. There was no significant difference between men’s and women’s responses. FSD: functional somatic disorder. PTSD: post-traumatic stress disorder. MCAS: mast cell activation syndrome.

Figure 2

Figure 2. Main cause for long COVID considered by senior internists in France. In the survey delineated in the legend of Figure 1, a second question was asked of senior French internists about the main cause of long COVID. The figure presents a graphical representation of the responses to this question. The question posed to participants was: “Among the hypotheses you selected in the initial question, which do you consider to be the primary cause?” The non-somatic causes, depicted in grey-green, account for a substantial proportion of the responses, amounting to 90%.

One striking fact is that 229/240 (95%) of French internists do not want to manage patients with long COVID on their own, contrary to most multi-systemic immune mediated inflammatory disorders. Many internists (111/240, 46%) do not want to take care of them anymore once the etiological assessment is carried out and does not highlight any objective anomaly. Even more, 69 (29%) wish they would not see any patient with long COVID in consultation. This is a good example of the rejection experienced by patients with FSD, which makes their fear of being labeled with this diagnosis quite understandable. This is partly due to a lack of doctors’ training for FSD diagnostic and treatment. Indeed, most internists, although they often quickly have the intuition that the patient has a FSD, are not aware of their specific positive criteria. Therefore, they usually retain this diagnosis by default, after a very broad biomedical work-up and often without telling the patient explicitly. Furthermore, even with a good knowledge of FSD, consultations are often difficult and sometimes frankly tedious for the doctor. Notably, the time of anamnesis is particularly long (easily an hour if one tries to be exhaustive) and difficult to synthesize afterwards. The mobilization of empathy must be maximum and requires a lot of energy. Last, the management of uncertainty is anxiogenic (“Doctor, how can you be sure that you have looked for everything?”). Thus, these consultations are very energy and time consuming, and most physicians fear them (66).

Therefore, almost all French internists endorse a multidisciplinary management of patients with long COVID, as they do for patients with FSD. Noteworthy, existing national management guidelines for long COVID (63, 67) also praise for such a holistic approach, modeled on existing recommendations for FSD (65, 68), even if FSD is not mentioned explicitly or even excluded (69). Indeed, such an approach is recommended for several other complex conditions without any detectable organic lesion, such as fibromyalgia (70) or chronic fatigue syndrome (71). Both graduated physical activity (72) and cognitive behavioral therapy (73, 74) proved efficient in individuals with long COVID. Physical rehabilitation is usually well tolerated if well explained and realized correctly (75). However, if the exercise intensity is initially too high, the occurrence of post exertional malaises can reinforce the fear of exercising. Although no trial has assessed the superiority of a multidisciplinary approach combining graduated physical activity and cognitive behavioral therapy, trials are ongoing (e.g., ECHAP COVID, https://clinicaltrials.gov/study/NCT05532904) and integrated programs have already provided high satisfaction rates among patients with severe long COVID (57). Such programs include the delivery of rational cognitive explanations for the symptoms and support for behavioral changes tailored to the patient. Many patients with very disabling long COVID, who benefited from this type of psycho-corporal treatment, have also reported their recovery story on the Norwegian site recoverynorway.org.

Conclusion

Along with Saunders et al. (76) we think that “it is time to break taboos based on a dualistic understanding of physical versus mental illness and bring in existing knowledge about functional somatic symptoms to provide improved explanations and treatments.”

Except for those patients who have an identified cause of prolonged symptoms, such as depression or PTSD or post intensive care physical sequelae, we argue to treat long COVID as a FSD, rather than waiting for hypothetical pharmacological treatments that biological studies might bring us in the future. It is therefore necessary to federate motivated and competent health care professionals to distribute the mainstays of treatment in a coordinated and synergistic way (77). In addition to the physicians, several other health care professionals are key actors of the patient’s recovery, such as psychiatrists, psychologists, physiotherapists, speech-language pathologists and teachers of adapted physical activity.

The position of the physician must probably remain central due to the physical nature of long COVID symptoms, with regular reassessment to not omit another associated disease. This is crucial to reassure the patient, so that he/she can concentrate on his/her personal physical and mental work. Along with general practitioners, internists certainly have a key role to play in the management of patients with the most severe conditions. Nevertheless, all health care professionals certainly need to be trained to better know the various mechanisms in play in the persistence of symptoms, avoid inappropriate behaviors and communication mistakes (78) and tailor patient-centered appropriate management, especially regarding the modalities of resuming physical activity. To be widely accepted, this proposal requires a radical change in the way mind–body interaction is viewed in the medical community and the general population. Less alarmist and more balanced media coverage should help the public to recognize the reality of FSD, understand its mechanisms and the potential for complete recovery.

Author contributions

BR: Writing – original draft, Writing – review & editing. EC: Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Acknowledgments

The authors thank Benoit Vokaer (HUB, Hôpital Erasme, ULB, Brussels, Belgium) and Jacques Pouchot (Hôpital Européen Georges Pompidou, Paris, France) for helpful discussion and careful reading of our manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Gen AI was used in the creation of this manuscript.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2025.1521472/full#supplementary-material

SUPPLEMENTARY FIGURE 1 | Demographics and practice patterns. The results of the demographic data and professional practice of 240 French internists who responded to our survey on long COVID are presented. This sample reflects the practice of internal medicine in France, with a higher proportion of men (A), an age distribution with most internists aged between 40 and 49 (B), and most of the practice in university or general hospital structures (C). The distribution of the number of long COVID patients treated by the respondents is shown in (D). A very small proportion of respondents do not treat any patients and more than one in three treat more than 50 patients. ESPIC, Private Health Establishment of Collective Interest.

SUPPLEMENTARY FIGURE 2 | Geographical distribution of survey respondents. The figure shows the geographical location of internists who responded to the long COVID survey. This distribution is consistent with the distribution of internists by region in France.

References

1. Davis, HE, McCorkell, L, Vogel, JM, and Topol, EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. (2023) 21:133–46. doi: 10.1038/s41579-022-00846-2

PubMed Abstract | Crossref Full Text | Google Scholar

2. Xie, Y, Choi, T, and Al-Aly, Z. Postacute sequelae of SARS-CoV-2 infection in the Pre-Delta, Delta, and omicron eras. N Engl J Med. (2024) 391:515–25. doi: 10.1056/NEJMoa2403211

PubMed Abstract | Crossref Full Text | Google Scholar

3. Pastorello, A, Meyer, L, Coste, J, Davisse-Paturet, C, de Lamballerie, X, Melchior, M, et al. Temporal changes in the risk of six-month post-covid symptoms: a national population-based cohort study. Am J Epidemiol. (2024) 194:162–71. doi: 10.1093/aje/kwae174

PubMed Abstract | Crossref Full Text | Google Scholar

4. Hoeg, TB, Ladhani, S, and Prasad, V. How methodological pitfalls have created widespread misunderstanding about long COVID. BMJ Evid Based Med. (2024) 29:142–6. doi: 10.1136/bmjebm-2023-112338

PubMed Abstract | Crossref Full Text | Google Scholar

5. Davis, HE, Assaf, GS, McCorkell, L, Wei, H, Low, RJ, Re'em, Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. (2021) 38:101019. doi: 10.1016/j.eclinm.2021.101019

PubMed Abstract | Crossref Full Text | Google Scholar

6. Soriano, JB, Murthy, S, Marshall, JC, Relan, P, and Diaz, JV. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. (2022) 22:e102–7. doi: 10.1016/S1473-3099(21)00703-9

PubMed Abstract | Crossref Full Text | Google Scholar

7. Ghosn, J, Piroth, L, Epaulard, O, Le Turnier, P, Mentre, F, Bachelet, D, et al. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clin Microbiol Infect. (2021) 27:1041.e1–4. doi: 10.1016/j.cmi.2021.03.012

PubMed Abstract | Crossref Full Text | Google Scholar

8. Cervia-Hasler, C, Bruningk, SC, Hoch, T, Fan, B, Muzio, G, Thompson, RC, et al. Persistent complement dysregulation with signs of thromboinflammation in active long Covid. Science. (2024) 383:eadg7942. doi: 10.1126/science.adg7942

PubMed Abstract | Crossref Full Text | Google Scholar

9. Klein, J, Wood, J, Jaycox, JR, Dhodapkar, RM, Lu, P, Gehlhausen, JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature. (2023) 623:139–48. doi: 10.1038/s41586-023-06651-y

PubMed Abstract | Crossref Full Text | Google Scholar

10. Phetsouphanh, C, Darley, DR, Wilson, DB, Howe, A, Munier, CML, Patel, SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. (2022) 23:210–6. doi: 10.1038/s41590-021-01113-x

PubMed Abstract | Crossref Full Text | Google Scholar

11. Patterson, BK, Guevara-Coto, J, Yogendra, R, Francisco, EB, Long, E, Pise, A, et al. Immune-based prediction of COVID-19 severity and chronicity decoded using machine learning. Front Immunol. (2021) 12:700782. doi: 10.3389/fimmu.2021.700782

PubMed Abstract | Crossref Full Text | Google Scholar

12. Schultheiss, C, Willscher, E, Paschold, L, Gottschick, C, Klee, B, Bosurgi, L, et al. Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19. J Med Virol. (2023) 95:e28364. doi: 10.1002/jmv.28364

PubMed Abstract | Crossref Full Text | Google Scholar

13. Sommen, SL, Havdal, LB, Selvakumar, J, Einvik, G, Leegaard, TM, Lund-Johansen, F, et al. Inflammatory markers and pulmonary function in adolescents and young adults 6 months after mild COVID-19. Front Immunol. (2022) 13:1081718. doi: 10.3389/fimmu.2022.1081718

PubMed Abstract | Crossref Full Text | Google Scholar

14. Yong, SJ, Halim, A, Halim, M, Liu, S, Aljeldah, M, Al Shammari, BR, et al. Inflammatory and vascular biomarkers in post-COVID-19 syndrome: a systematic review and meta-analysis of over 20 biomarkers. Rev Med Virol. (2023) 33:e2424. doi: 10.1002/rmv.2424

PubMed Abstract | Crossref Full Text | Google Scholar

15. Altmann, DM, Whettlock, EM, Liu, S, Arachchillage, DJ, and Boyton, RJ. The immunology of long COVID. Nat Rev Immunol. (2023) 23:618–34. doi: 10.1038/s41577-023-00904-7

PubMed Abstract | Crossref Full Text | Google Scholar

16. Mehandru, S, and Merad, M. Pathological sequelae of long-haul COVID. Nat Immunol. (2022) 23:194–202. doi: 10.1038/s41590-021-01104-y

PubMed Abstract | Crossref Full Text | Google Scholar

17. Scherlinger, M, Felten, R, Gallais, F, Nazon, C, Chatelus, E, Pijnenburg, L, et al. Refining "Long-COVID" by a prospective multimodal evaluation of patients with long-term symptoms attributed to SARS-CoV-2 infection. Infect Dis Ther. (2021) 10:1747–63. doi: 10.1007/s40121-021-00484-w

PubMed Abstract | Crossref Full Text | Google Scholar

18. Zuo, W, He, D, Liang, C, Du, S, Hua, Z, Nie, Q, et al. The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. Lancet Infect Dis. (2024) 24:845–55. doi: 10.1016/S1473-3099(24)00171-3

Crossref Full Text | Google Scholar

19. Sun, Z, Shi, C, and Jin, L. Mechanisms by which SARS-CoV-2 invades and damages the central nervous system: apart from the immune response and inflammatory storm, what Else do we know? Viruses. (2024) 16:1–20. doi: 10.3390/v16050663

PubMed Abstract | Crossref Full Text | Google Scholar

20. Klein, RS. Mechanisms of coronavirus infectious disease 2019-related neurologic diseases. Curr Opin Neurol. (2022) 35:392–8. doi: 10.1097/WCO.0000000000001049

PubMed Abstract | Crossref Full Text | Google Scholar

21. Kanberg, N, Simren, J, Eden, A, Andersson, LM, Nilsson, S, Ashton, NJ, et al. Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. EBioMedicine. (2021) 70:103512. doi: 10.1016/j.ebiom.2021.103512

PubMed Abstract | Crossref Full Text | Google Scholar

22. de Melo, GD, Lazarini, F, Levallois, S, Hautefort, C, Michel, V, Larrous, F, et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med. (2021) 13:eabf8396. doi: 10.1126/scitranslmed.abf8396

PubMed Abstract | Crossref Full Text | Google Scholar

23. Yao, Q, Doyle, ME, Liu, QR, Appleton, A, O'Connell, JF, Weng, NP, et al. Long-term dysfunction of taste papillae in SARS-CoV-2. NEJM Evid. (2023) 2:1–11. doi: 10.1056/evidoa2300046

PubMed Abstract | Crossref Full Text | Google Scholar

24. Li, Y, Choudhary, MC, Regan, J, Boucau, J, Nathan, A, Speidel, T, et al. SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. Sci Transl Med. (2024) 16:eadk1599. doi: 10.1126/scitranslmed.adk1599

PubMed Abstract | Crossref Full Text | Google Scholar

25. Erlandson, KM, Geng, LN, Selvaggi, CA, Thaweethai, T, Chen, P, Erdmann, NB, et al. Differentiation of prior SARS-CoV-2 infection and Postacute sequelae by standard clinical laboratory measurements in the RECOVER cohort. Ann Intern Med. (2024) 177:1209–21. doi: 10.7326/M24-0737

PubMed Abstract | Crossref Full Text | Google Scholar

26. Lund Berven, L, Selvakumar, J, Havdal, L, Stiansen-Sonerud, T, Einvik, G, Leegaard, TM, et al. Inflammatory markers, pulmonary function, and clinical symptoms in acute COVID-19 among non-hospitalized adolescents and Young adults. Front Immunol. (2022) 13:837288. doi: 10.3389/fimmu.2022.837288

PubMed Abstract | Crossref Full Text | Google Scholar

27. Selvakumar, J, Havdal, LB, Drevvatne, M, Brodwall, EM, Lund Berven, L, Stiansen-Sonerud, T, et al. Prevalence and characteristics associated with Post-COVID-19 condition among nonhospitalized adolescents and Young adults. JAMA Netw Open. (2023) 6:e235763. doi: 10.1001/jamanetworkopen.2023.5763

PubMed Abstract | Crossref Full Text | Google Scholar

28. Sneller, MC, Liang, CJ, Marques, AR, Chung, JY, Shanbhag, SM, Fontana, JR, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med. (2022) 175:969–79. doi: 10.7326/M21-4905

PubMed Abstract | Crossref Full Text | Google Scholar

29. Sudre, CH, Murray, B, Varsavsky, T, Graham, MS, Penfold, RS, Bowyer, RC, et al. Attributes and predictors of long COVID. Nat Med. (2021) 27:626–31. doi: 10.1038/s41591-021-01292-y

PubMed Abstract | Crossref Full Text | Google Scholar

30. Townsend, L, Dowds, J, O'Brien, K, Sheill, G, Dyer, AH, O'Kelly, B, et al. Persistent poor health after COVID-19 is not associated with respiratory complications or initial disease severity. Ann Am Thorac Soc. (2021) 18:997–1003. doi: 10.1513/AnnalsATS.202009-1175OC

PubMed Abstract | Crossref Full Text | Google Scholar

31. Chee, YJ, Fan, BE, Young, BE, Dalan, R, and Lye, DC. Clinical trials on the pharmacological treatment of long COVID: a systematic review. J Med Virol. (2023) 95:e28289. doi: 10.1002/jmv.28289

PubMed Abstract | Crossref Full Text | Google Scholar

32. Chou, R, Herman, E, Ahmed, A, Anderson, J, Selph, S, Dana, T, et al. Long COVID definitions and models of care: a scoping review. Ann Intern Med. (2024) 177:929–40. doi: 10.7326/M24-0677

PubMed Abstract | Crossref Full Text | Google Scholar

33. Geng, LN, Bonilla, H, Hedlin, H, Jacobson, KB, Tian, L, Jagannathan, P, et al. Nirmatrelvir-ritonavir and symptoms in adults with Postacute sequelae of SARS-CoV-2 infection: the STOP-PASC randomized clinical trial. JAMA Intern Med. (2024) 184:1024–34. doi: 10.1001/jamainternmed.2024.2007

PubMed Abstract | Crossref Full Text | Google Scholar

34. Zeraatkar, D, Ling, M, Kirsh, S, Jassal, T, Shahab, M, Movahed, H, et al. Interventions for the management of long covid (post-covid condition): living systematic review. BMJ. (2024) 387:e081318. doi: 10.1136/bmj-2024-081318

PubMed Abstract | Crossref Full Text | Google Scholar

35. Robineau, O, Zins, M, Touvier, M, Wiernik, E, Lemogne, C, de Lamballerie, X, et al. Long-lasting symptoms after an acute COVID-19 infection and factors associated with their resolution. JAMA Netw Open. (2022) 5:e2240985. doi: 10.1001/jamanetworkopen.2022.40985

PubMed Abstract | Crossref Full Text | Google Scholar

36. Cristillo, V, Pilotto, A, Piccinelli, SC, Gipponi, S, Leonardi, M, Bezzi, M, et al. Predictors of "brain fog" 1 year after COVID-19 disease. Neurol Sci. (2022) 43:5795–7. doi: 10.1007/s10072-022-06285-4

PubMed Abstract | Crossref Full Text | Google Scholar

37. Hirschtick, JL, Titus, AR, Slocum, E, Power, LE, Hirschtick, RE, Elliott, MR, et al. Population-based estimates of Post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) prevalence and characteristics. Clin Infect Dis. (2021) 73:2055–64. doi: 10.1093/cid/ciab408

PubMed Abstract | Crossref Full Text | Google Scholar

38. Townsend, L, Moloney, D, Finucane, C, McCarthy, K, Bergin, C, Bannan, C, et al. Fatigue following COVID-19 infection is not associated with autonomic dysfunction. PLoS One. (2021) 16:e0247280. doi: 10.1371/journal.pone.0247280

PubMed Abstract | Crossref Full Text | Google Scholar

39. Wang, S, Quan, L, Chavarro, JE, Slopen, N, Kubzansky, LD, Koenen, KC, et al. Associations of depression, anxiety, worry, perceived stress, and loneliness prior to infection with risk of Post-COVID-19 conditions. JAMA Psychiatry. (2022) 79:1081–91. doi: 10.1001/jamapsychiatry.2022.2640

PubMed Abstract | Crossref Full Text | Google Scholar

40. Shevlin, M, McBride, O, Murphy, J, Miller, JG, Hartman, TK, Levita, L, et al. Anxiety, depression, traumatic stress and COVID-19-related anxiety in the UK general population during the COVID-19 pandemic. BJPsych Open. (2020) 6:e125. doi: 10.1192/bjo.2020.109

PubMed Abstract | Crossref Full Text | Google Scholar

41. Engelmann, P, Lowe, B, Brehm, TT, Weigel, A, Ullrich, F, Addo, MM, et al. Risk factors for worsening of somatic symptom burden in a prospective cohort during the COVID-19 pandemic. Front Psychol. (2022) 13:1022203. doi: 10.3389/fpsyg.2022.1022203

PubMed Abstract | Crossref Full Text | Google Scholar

42. Engelmann, P, Reinke, M, Stein, C, Salzmann, S, Löwe, B, Toussaint, A, et al. Psychological factors associated with Long COVID: a systematic review and meta-analysis, Psychological factors associated with Long COVID: a systematic review and meta-analysis. eClinicalMedicine. (2024) 74:102756. doi: 10.1016/j.eclinm.2024.102756

PubMed Abstract | Crossref Full Text | Google Scholar

43. Al-Aly, Z, Davis, H, McCorkell, L, Soares, L, Wulf-Hanson, S, Iwasaki, A, et al. Long COVID science, research and policy. Nat Med. (2024) 30:2148–64. doi: 10.1038/s41591-024-03173-6

Crossref Full Text | Google Scholar

44. Raj, SR, Arnold, AC, Barboi, A, Claydon, VE, Limberg, JK, Lucci, VM, et al. Long-COVID postural tachycardia syndrome: an American autonomic society statement. Clin Auton Res. (2021) 31:365–8. doi: 10.1007/s10286-021-00798-2

PubMed Abstract | Crossref Full Text | Google Scholar

45. Ammar, A, Distinguin, L, Chetrit, A, Safa, D, Hans, S, Carlier, R, et al. Transient modifications of the olfactory bulb on MR follow-up of COVID-19 patients with related olfactory dysfunction. J Neuroradiol. (2022) 49:329–32. doi: 10.1016/j.neurad.2022.03.003

PubMed Abstract | Crossref Full Text | Google Scholar

46. Guedj, E, Campion, JY, Dudouet, P, Kaphan, E, Bregeon, F, Tissot-Dupont, H, et al. (18) F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging. (2021) 48:2823–33. doi: 10.1007/s00259-021-05215-4

PubMed Abstract | Crossref Full Text | Google Scholar

47. Dressing, A, Bormann, T, Blazhenets, G, Schroeter, N, Walter, LI, Thurow, J, et al. Neuropsychologic profiles and cerebral glucose metabolism in neurocognitive Long COVID syndrome. J Nucl Med. (2022) 63:1058–63. doi: 10.2967/jnumed.121.262677

PubMed Abstract | Crossref Full Text | Google Scholar

48. Meyer, PT, Hellwig, S, Blazhenets, G, and Hosp, JA. Molecular imaging findings on acute and Long-term effects of COVID-19 on the brain: a systematic review. J Nucl Med. (2022) 63:971–80. doi: 10.2967/jnumed.121.263085

PubMed Abstract | Crossref Full Text | Google Scholar

49. Wessely, S, Nimnuan, C, and Sharpe, M. Functional somatic syndromes: one or many? Lancet. (1999) 354:936–9. doi: 10.1016/S0140-6736(98)08320-2

PubMed Abstract | Crossref Full Text | Google Scholar

50. Dimsdale, JE, Creed, F, Escobar, J, Sharpe, M, Wulsin, L, Barsky, A, et al. Somatic symptom disorder: an important change in DSM. J Psychosom Res. (2013) 75:223–8. doi: 10.1016/j.jpsychores.2013.06.033

PubMed Abstract | Crossref Full Text | Google Scholar

51. Sharpe, M, and Carson, A. "unexplained" somatic symptoms, functional syndromes, and somatization: do we need a paradigm shift? Ann Intern Med. (2001) 134:926–30. doi: 10.7326/0003-4819-134-9_part_2-200105011-00018

Crossref Full Text | Google Scholar

52. Lowe, B, Toussaint, A, Rosmalen, JGM, Huang, WL, Burton, C, Weigel, A, et al. Persistent physical symptoms: definition, genesis, and management. Lancet. (2024) 403:2649–62. doi: 10.1016/S0140-6736(24)00623-8

Crossref Full Text | Google Scholar

53. Fink, P, and Schroder, A. One single diagnosis, bodily distress syndrome, succeeded to capture 10 diagnostic categories of functional somatic syndromes and somatoform disorders. J Psychosom Res. (2010) 68:415–26. doi: 10.1016/j.jpsychores.2010.02.004

PubMed Abstract | Crossref Full Text | Google Scholar

54. Elkayam, S, Lojek, E, Sekowski, M, Zarnecka, D, Egbert, A, Wyszomirska, J, et al. Factors associated with prolonged COVID-related PTSD-like symptoms among adults diagnosed with mild COVID-19 in Poland. Front Psychol. (2024) 15:1358979. doi: 10.3389/fpsyg.2024.1358979

PubMed Abstract | Crossref Full Text | Google Scholar

55. Qiu, D, Li, Y, Li, L, He, J, Ouyang, F, and Xiao, S. Infectious disease outbreak and Post-traumatic stress symptoms: a systematic review and Meta-analysis. Front Psychol. (2021) 12:668784. doi: 10.3389/fpsyg.2021.668784

PubMed Abstract | Crossref Full Text | Google Scholar

56. Nagarajan, R, Krishnamoorthy, Y, Basavarachar, V, and Dakshinamoorthy, R. Prevalence of post-traumatic stress disorder among survivors of severe COVID-19 infections: a systematic review and meta-analysis. J Affect Disord. (2022) 299:52–9. doi: 10.1016/j.jad.2021.11.040

PubMed Abstract | Crossref Full Text | Google Scholar

57. Gouraud, C, Thoreux, P, Ouazana-Vedrines, C, Pitron, V, Betouche, S, Bolloch, K, et al. Patients with persistent symptoms after COVID-19 attending a multidisciplinary evaluation: characteristics, medical conclusions, and satisfaction. J Psychosom Res. (2023) 174:111475. doi: 10.1016/j.jpsychores.2023.111475

PubMed Abstract | Crossref Full Text | Google Scholar

58. Joffe, AR, and Elliott, A. Long COVID as a functional somatic symptom disorder caused by abnormally precise prior expectations during Bayesian perceptual processing: a new hypothesis and implications for pandemic response. SAGE Open Med. (2023) 11:20503121231194400. doi: 10.1177/20503121231194400

PubMed Abstract | Crossref Full Text | Google Scholar

59. Parotto, M, Gyongyosi, M, Howe, K, Myatra, SN, Ranzani, O, Shankar-Hari, M, et al. Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations. Lancet Respir Med. (2023) 11:739–54. doi: 10.1016/S2213-2600(23)00239-4

PubMed Abstract | Crossref Full Text | Google Scholar

60. Troscher, A, Gebetsroither, P, Rindler, M, Bohm, V, Dormann, R, von Oertzen, T, et al. High somatization rates, frequent spontaneous recovery, and a lack of organic biomarkers in Post-Covid-19 condition. Brain Behav. (2024) 14:e70087. doi: 10.1002/brb3.70087

PubMed Abstract | Crossref Full Text | Google Scholar

61. Seighali, N, Abdollahi, A, Shafiee, A, Amini, MJ, Teymouri Athar, MM, Safari, O, et al. The global prevalence of depression, anxiety, and sleep disorder among patients coping with Post COVID-19 syndrome (long COVID): a systematic review and meta-analysis. BMC Psychiatry. (2024) 24:105. doi: 10.1186/s12888-023-05481-6

PubMed Abstract | Crossref Full Text | Google Scholar

62. Saheb Sharif-Askari, F, Ali Hussain Alsayed, H, Saheb Sharif-Askari, N, Al Sayed Hussain, A, Al-Muhsen, S, and Halwani, R. Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients. Sci Rep. (2024) 14:25901. doi: 10.1038/s41598-024-76472-0

PubMed Abstract | Crossref Full Text | Google Scholar

63. Haute Autorité de Santé (HAS). Symptomes prolongés suite à une COVID 19 de l'adulte. DIagnostic et prise en charge. (2024); Available online at: www.has-sante.fr/jcms/p_3237041/fr/symptomes-prolonges-suite-a-une-covid-19-de-l-adulte-diagnostic-et-prise-en-charge (Accessed March 21, 2025).

Google Scholar

64. Kachaner, A, Harim, M, Combier, A, Trouvin, AP, Avouac, J, Ranque, B, et al. Management perspectives from patients with fibromyalgia experiences with the healthcare pathway: a qualitative study. Front Med. (2023) 10:1231951. doi: 10.3389/fmed.2023.1231951

PubMed Abstract | Crossref Full Text | Google Scholar

65. Henningsen, P, Gundel, H, Kop, WJ, Lowe, B, Martin, A, Rief, W, et al. Persistent physical symptoms as perceptual dysregulation: a Neuropsychobehavioral model and its clinical implications. Psychosom Med. (2018) 80:422–31. doi: 10.1097/PSY.0000000000000588

PubMed Abstract | Crossref Full Text | Google Scholar

66. Ranque, B, and Nardon, O. Medically unexplained symptoms' care in internal medicine: a paradigm of doctor-patient relationship in situation of uncertainty. Rev Med Interne. (2017) 38:458–66. doi: 10.1016/j.revmed.2016.12.005

PubMed Abstract | Crossref Full Text | Google Scholar

67. National Institute for health and care excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19: management (2024). Available online at: www.nice.org.uk/guidance/ng188/chapter/5-Management

Google Scholar

68. van Dessel, N, den Boeft, M, van der Wouden, JC, Kleinstauber, M, Leone, SS, Terluin, B, et al. Non-pharmacological interventions for somatoform disorders and medically unexplained physical symptoms (MUPS) in adults. Cochrane Database Syst Rev. (2014) 2014:CD011142. doi: 10.1002/14651858.CD011142.pub2

PubMed Abstract | Crossref Full Text | Google Scholar

69. Lemogne, C, Gouraud, C, Ouazana Vedrines, C, Pritschkat, C, Rotenberg, L, Horn, M, et al. National committee statement as a missed opportunity to acknowledge the relevance of a biopsychosocial approach in understanding long COVID. J Psychosom Res. (2024) 186:111596. doi: 10.1016/j.jpsychores.2024.111596

PubMed Abstract | Crossref Full Text | Google Scholar

70. Macfarlane, GJ, Kronisch, C, Dean, LE, Atzeni, F, Hauser, W, Fluss, E, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. (2017) 76:318–28. doi: 10.1136/annrheumdis-2016-209724

PubMed Abstract | Crossref Full Text | Google Scholar

71. White, PD, Goldsmith, KA, Johnson, AL, Potts, L, Walwyn, R, DeCesare, JC, et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet. (2011) 377:823–36. doi: 10.1016/S0140-6736(11)60096-2

PubMed Abstract | Crossref Full Text | Google Scholar

72. Pouliopoulou, DV, Macdermid, JC, Saunders, E, Peters, S, Brunton, L, Miller, E, et al. Rehabilitation interventions for physical capacity and quality of life in adults with Post-COVID-19 condition: a systematic review and Meta-analysis. JAMA Netw Open. (2023) 6:e2333838. doi: 10.1001/jamanetworkopen.2023.33838

PubMed Abstract | Crossref Full Text | Google Scholar

73. Frisk, B, Jurgensen, M, Espehaug, B, Njoten, KL, Softeland, E, Aarli, BB, et al. A safe and effective micro-choice based rehabilitation for patients with long COVID: results from a quasi-experimental study. Sci Rep. (2023) 13:9423. doi: 10.1038/s41598-023-35991-y

PubMed Abstract | Crossref Full Text | Google Scholar

74. Kuut, TA, Muller, F, Csorba, I, Braamse, A, Aldenkamp, A, Appelman, B, et al. Efficacy of cognitive-behavioral therapy targeting severe fatigue following coronavirus disease 2019: results of a randomized controlled trial. Clin Infect Dis. (2023) 77:687–95. doi: 10.1093/cid/ciad257

PubMed Abstract | Crossref Full Text | Google Scholar

75. Tryfonos, A, Pourhamidi, K, Jornaker, G, Engvall, M, Eriksson, L, Elhallos, S, et al. Functional limitations and exercise intolerance in patients with Post-COVID condition: a randomized crossover clinical trial. JAMA Netw Open. (2024) 7:e244386. doi: 10.1001/jamanetworkopen.2024.4386

PubMed Abstract | Crossref Full Text | Google Scholar

76. Saunders, C, Sperling, S, and Bendstrup, E. A new paradigm is needed to explain long COVID. Lancet Respir Med. (2023) 11:e12–3. doi: 10.1016/S2213-2600(22)00501-X

PubMed Abstract | Crossref Full Text | Google Scholar

77. Leaviss, J, Davis, S, Ren, S, Hamilton, J, Scope, A, Booth, A, et al. Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation. Health Technol Assess. (2020) 24:1–490. doi: 10.3310/hta24460

PubMed Abstract | Crossref Full Text | Google Scholar

78. Weiland, A, Blankenstein, AH, Van Saase, JL, Van der Molen, HT, Jacobs, ME, Abels, DC, et al. Training medical specialists to communicate better with patients with medically unexplained physical symptoms (MUPS). A randomized, controlled trial. PLoS One. (2015) 10:e0138342. doi: 10.1371/journal.pone.0138342

PubMed Abstract | Crossref Full Text | Google Scholar